Approximately 30% to 40% of hospitalized patients with acute coronary syndrome are older adults, among whom the majority of cardiovascular-related deaths occur. When compared to younger patients, these individuals generally experience inferior clinical outcomes. Most clinical trials assessing the efficacy and safety of various therapeutics have primarily enrolled patients under the age of 75, in addition to excluding those with geriatric complexities. In this review, we emphasize the need for a personalized and comprehensive approach to pharmacotherapy for coronary heart disease and acute coronary syndrome in older adults, considering concomitant geriatric syndromes and age-related factors to optimize treatment outcomes while minimizing potential risks and complications. In the realm of clinical practice, cardiovascular and geriatric risks are closely intertwined, with both being significant factors in determining treatments aimed at reducing negative outcomes and attaining health conditions most valued by older adults.
Keyphrases
- acute coronary syndrome
- end stage renal disease
- clinical trial
- physical activity
- newly diagnosed
- coronary artery disease
- ejection fraction
- chronic kidney disease
- percutaneous coronary intervention
- peritoneal dialysis
- human health
- healthcare
- public health
- prognostic factors
- mental health
- small molecule
- heart failure
- type diabetes
- risk factors
- metabolic syndrome
- antiplatelet therapy
- hip fracture
- adipose tissue
- coronary artery bypass grafting
- risk assessment
- weight loss
- social media
- skeletal muscle
- climate change
- atrial fibrillation